Comparison of 3 Quantitative HCV RNA Assays - Accuracy of Baseline Viral Load to Predict Treatment Outcome in Chronic Hepatitis C

References

• Gretch DR, Dela Rosa C, Corey L, Carithers RL. Assessment of hepatitis C viremia using molecular amplification technologies. Viral Hepatitis Rev 1996; 2: 85–96.
   Google Scholar
• Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501–4.
   Google Scholar
• Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–6.
   Google Scholar
• Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Rémiré F, Métreau JM, Zafrani ES, Duval J, Dhumeaux D. Factors affecting treatment responses to interferon-alfa in chronic hepatitis C. J Infect Dis 1996; 174: 1–7.
   PubMed Web of Science ®Google Scholar
• Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351–4.
   PubMed Web of Science ®Google Scholar
• Yun ZB, Reichard O, Chen M, Lundeberg J, Norkrans G, Frydén A, Sönnerborg A, Weiland O. Serum hepatitis C virus RNA levels in chronic hepatitis C—Importance for outcome of interferon alfa-2b treatment. Scand J Infect Dis 1994; 26: 263–70.
   Google Scholar
• Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka M, Arakawa Y. Omata M for the Tokyo-Chiba hepatitis research group. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113: 558–66.
   Google Scholar
• Hino K, Okuda M, Konishi T, Ishiko H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alfa therapy. Dig Dis Sci 1995; 40: 14–20.
   Google Scholar
• Ampurdanés S, Olmedo E, Maluenda MD, Forns X, Lopez-Labrador FX, Costa J, Sanchez-Tapias JM, de Anta MT, Rodes J. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 1996; 25: 827–32.
   Google Scholar
• Gretch D, Corey L, Wilson J, Dela Rossa C, Wilson R, Carithers R, Busch M, Hart J, Sayers M, Han J. Assessment of hepatitis C virus RNA levels by quantitative competetive RNA polymerase chain reaction: high titer viremia correlates with advanced stage of disease. J Infect Dis 1994; 168: 1219–25.
   Google Scholar
• Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T. Quantitation of hepatitis C virus RNA in serum of asymtomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545–50.
   Google Scholar
• Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S, Orito E, Mizokami M. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alfa therapy in chronic hepatitis C patients. J Med Virol 1996; 48: 354–9.
   Google Scholar
• Roth WK, Lee JH, Ru¨ster B, Zeuzem S. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J Clin Microbiol 1996; 34: 261–4.
   Google Scholar
• Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997; 35: 187–92.
   Google Scholar
• Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: can we trust the assays? Hepatology 1997; 26: 1–4.
   PubMed Web of Science ®Google Scholar
• Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O and the Swedish study group. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83–7.
   Google Scholar
• Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, Ahle D, Chang CA. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucl Acids Symp Ser 1991; 24: 197–200.
   PubMedGoogle Scholar
• Detmer J, Lagier R, Flynn J, Zayati C, Kollberg J, Collins M, Urdea M, Sanchez-Pescador R. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996; 34: 901–7.
   Google Scholar
• Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa-2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26: 1640–5.
   Google Scholar
• Stuyver L, Rossau L, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093–102.
   Google Scholar
• Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347–56.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946–54.
   Google Scholar